Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review

被引:6
|
作者
Arhip, Loredana [1 ,2 ]
Brox-Torrecilla, Noemi [3 ]
Romero, Inmaculada [4 ]
Motilla, Marta [1 ,2 ]
Serrano-Moreno, Clara [1 ,2 ]
Miguelez, Maria [5 ]
Cuerda, Cristina [1 ,2 ,6 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Unidad Nutr Clin & Dietet, Calle Doctor Esquerdo 46, Madrid 28007, Spain
[2] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[3] Hosp Univ Ramon & Cajal, Madrid, Spain
[4] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[5] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[6] Univ Complutense Madrid, Madrid, Spain
关键词
Methylmalonic acidemia and homocystinuria; cblC type; Late-onset; MMACHC protein; COBALAMIN C DEFICIENCY; RENAL THROMBOTIC MICROANGIOPATHY; PULMONARY ARTERIAL-HYPERTENSION; COMBINED HOMOCYSTINURIA; CLINICAL HETEROGENEITY; ACIDURIA CBLC; PATIENT; ADOLESCENT; DISORDER; MUTATION;
D O I
10.1186/s13023-024-03021-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
IntroductionCombined methylmalonic acidemia and homocystinuria, cblC type is an inborn error of intracellular cobalamin metabolism and the most common one. The age of onset ranges from prenatal to adult. The disease is characterised by an elevation of methylmalonic acid (MMA) and homocysteine and a decreased production of methionine. The aim is to review existing scientific literature of all late onset cblC patients in terms of clinical symptoms, diagnosis, and outcome.MethodsA bibliographic database search was undertaken in PubMed (MEDLINE) complemented by a reference list search. We combined search terms regarding cblC disease and late onset. Two review authors performed the study selection, data extraction and quality assessment.ResultsOf the sixty-five articles included in this systematic review, we collected a total of 199 patients. The most frequent clinical symptoms were neuropathy/myelopathy, encephalopathy, psychiatric symptoms, thrombotic microangiopathy, seizures, kidney disease, mild to severe pulmonary hypertension with heart failure and thrombotic phenomena. There were different forms of supplementation used in the different studies collected and, within these studies, some patients received several treatments sequentially and/or concomitantly. The general outcome was: 64 patients recovered, 78 patients improved, 4 patients did not improve, or the disease progressed, and 12 patients died.ConclusionsMost scientific literature regarding the late onset cblC disease comes from case reports and case series. In most cases treatment initiation led to an improvement and even recovery of some patients. The lack of complete recovery underlines the necessity for increased vigilance in unclear clinical symptoms for cblC disease.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Clinical guidelines for late-onset Pompe disease
    Barba-Romero, Miguel A.
    Barrot, Emilia
    Bautista-Lorite, Juan
    Gutierrez-Rivas, Eduardo
    Illa, Isabel
    Jimenez, Luis M.
    Ley-Martos, Myriam
    Lopez de Munain, Adolfo
    Pardo, Julio
    Pascual-Pascual, Samuel I.
    Perez-Lopez, Jordi
    Solera, Jesus
    Vilchez-Padilla, Juan J.
    REVISTA DE NEUROLOGIA, 2012, 54 (08) : 497 - 507
  • [22] Guidelines for monitoring late-onset Pompe disease
    Gutierrez-Rivas, Eduardo
    Illa, Isabel
    Pascual-Pascual, Samuel I.
    Perez-Lopez, Jordi
    Vilchez-Padilla, Juan J.
    Bautista-Lorite, Juan
    Barrot, Emilia
    de Munain, Adolfo Lopez
    REVISTA DE NEUROLOGIA, 2015, 60 (07) : 321 - 328
  • [23] Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature
    Malhotra, Konark
    Carrington, David C.
    Liebeskind, David S.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (08) : E172 - E175
  • [24] Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis
    Naseri, Amirreza
    Nasiri, Ehsan
    Sahraian, Mohammad Ali
    Daneshvar, Sara
    Talebi, Mahnaz
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [25] Screening for late-onset Pompe disease in Finland
    Palmio, Johanna
    Auranen, Mari
    Kiuru-Enari, Sari
    Lofberg, Mervi
    Bodamer, Olaf
    Udd, Bjarne
    NEUROMUSCULAR DISORDERS, 2014, 24 (11) : 982 - 985
  • [26] The impact of antibodies in late-onset Pompe disease: A case series and literature review
    Patel, Trusha T.
    Banugaria, Suhrad G.
    Case, Laura E.
    Wenninger, Stephan
    Schoser, Benedikt
    Kishnani, Priya S.
    MOLECULAR GENETICS AND METABOLISM, 2012, 106 (03) : 301 - 309
  • [27] VERY LATE-ONSET SANDHOFF DISEASE PRESENTING AS KENNEDY DISEASE
    Chardon, Jodi Warman
    Bourque, Pierre R.
    Geraghty, Michael T.
    Boycott, Kym M.
    MUSCLE & NERVE, 2015, 52 (06) : 1135 - 1136
  • [28] Treatment Dilemma in Children with Late-Onset Pompe Disease
    Faraguna, Martha Caterina
    Crescitelli, Viola
    Fornari, Anna
    Barzaghi, Silvia
    Savasta, Salvatore
    Foiadelli, Thomas
    Veraldi, Daniele
    Paoletti, Matteo
    Pichiecchio, Anna
    Gasperini, Serena
    GENES, 2023, 14 (02)
  • [29] Etiology and Pathogenesis of Late-Onset Alzheimer’s Disease
    Brian J. Balin
    Alan P. Hudson
    Current Allergy and Asthma Reports, 2014, 14
  • [30] Cyclophosphamide-induced late-onset lung disease
    Hamada, K
    Nagai, S
    Kitaichi, M
    Jin, G
    Shigematsu, M
    Nagao, T
    Sato, A
    Mishima, M
    INTERNAL MEDICINE, 2003, 42 (01) : 82 - 87